Feasibility of non-TBI conditioning with busulfan and fludarabine for allogeneic stem cell transplantation in lymphoid malignancy.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Korean Association of Internal Medicine Country of Publication: Korea (South) NLM ID: 8712418 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2005-6648 (Electronic) Linking ISSN: 12263303 NLM ISO Abbreviation: Korean J Intern Med Subsets: MEDLINE
    • Publication Information:
      Original Publication: [Seoul] : Korean Association of Internal Medicine
    • Subject Terms:
      Stem Cell Transplantation*/adverse effects ; Stem Cell Transplantation*/mortality; Busulfan/*therapeutic use ; Myeloablative Agonists/*therapeutic use ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/*therapy ; Transplantation Conditioning/*methods ; Vidarabine/*analogs & derivatives; Adolescent ; Adult ; Busulfan/adverse effects ; Chi-Square Distribution ; Disease-Free Survival ; Drug Therapy, Combination ; Feasibility Studies ; Female ; Graft vs Host Disease/etiology ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Multivariate Analysis ; Myeloablative Agonists/adverse effects ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/mortality ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/surgery ; Proportional Hazards Models ; Republic of Korea ; Retrospective Studies ; Risk Assessment ; Risk Factors ; Time Factors ; Transplantation Conditioning/adverse effects ; Transplantation Conditioning/mortality ; Transplantation, Homologous ; Treatment Outcome ; Vidarabine/adverse effects ; Vidarabine/therapeutic use ; Young Adult
    • Abstract:
      Background/aims: This retrospective study evaluated the transplantation outcomes of patients with adult lymphoid malignancies who received chemotherapy-based conditioning with busulfan and fludarabine (BuFlu) and busulfan and cyclophosphamide (BuCy2).
      Methods: Thirty-eight patients (34 with acute lymphoblastic leukemia and 4 with lymphoblastic lymphoma) were included in the current study. The conditioning regimen was BuCy2 for 14 patients and BuFlu for the remaining 24 patients. Eight and 13 patients were high risk disease in the BuCy2 and BuFlu groups, respectively.
      Results: The cumulative incidence of grade II-IV acute graft-versus-host disease (GVHD) was 56.5% and 55.2% and that of extensive chronic GVHD 17.0% and 55.6% (p = 0.018) for the BuFlu and BuCy2 groups, respectively. The 3-year relapse rate was 27.8% and 31.4% and 3-year overall survival 34.3% and 46.8% for the BuFlu and BuCy2 groups, respectively. Treatment-related mortality (TRM) was significantly lower in the BuFlu group (16.9%) than in the BuCy2 group (57.1%, p = 0.010). In multivariate analyses, the BuFlu regimen was identified as an independent favorable risk factor for TRM (hazard ratio [HR], 0.036; p = 0.017) and extensive chronic GVHD (HR, 0.168; p = 0.034).
      Conclusions: Our BuFlu regimen would appear to be an acceptable conditioning option for lymphoid malignancies, including high-risk diseases. It was safely administered with a lower TRM rate than BuCy2 conditioning.
    • References:
      Blood. 1992 May 15;79(10):2578-82. (PMID: 1586710)
      Bone Marrow Transplant. 1995 Jun;15(6):825-8. (PMID: 7581076)
      Blood. 1990 Apr 15;75(8):1723-7. (PMID: 2328321)
      J Clin Oncol. 1991 Jan;9(1):175-88. (PMID: 1702143)
      Haematologica. 2000 Oct;85(10):1060-7. (PMID: 11025598)
      Bone Marrow Transplant. 1997 Dec;20(11):909-13. (PMID: 9422468)
      Blood. 1995 Apr 15;85(8):2263-8. (PMID: 7718899)
      Blood. 1997 Apr 15;89(8):3055-60. (PMID: 9108427)
      Br J Haematol. 1996 Jun;93(3):637-45. (PMID: 8652385)
      J Pediatr Hematol Oncol. 2004 Feb;26(2):91-7. (PMID: 14767194)
      Bone Marrow Transplant. 2007 Jul;40(2):105-10. (PMID: 17468775)
      Hepatology. 1996 Oct;24(4):830-7. (PMID: 8855185)
      Cancer Chemother Pharmacol. 1989;24(6):386-90. (PMID: 2791192)
      Korean J Intern Med. 2009 Dec;24(4):287-98. (PMID: 19949725)
      Biol Blood Marrow Transplant. 2002;8(9):493-500. (PMID: 12374454)
      Am J Med. 1980 Aug;69(2):204-17. (PMID: 6996481)
      Bone Marrow Transplant. 1994 Nov;14(5):759-65. (PMID: 7889009)
      Blood. 2001 Dec 15;98(13):3569-74. (PMID: 11739158)
      Br J Haematol. 2002 Dec;119(4):1115-24. (PMID: 12472596)
      J Clin Oncol. 2000 Jan;18(2):340-7. (PMID: 10637248)
      Transplant Proc. 1996 Dec;28(6):3101. (PMID: 8962201)
      Blood. 2001 Nov 15;98(10):2942-7. (PMID: 11698275)
      Bone Marrow Transplant. 2005 Aug;36(4):337-41. (PMID: 15968296)
      Bone Marrow Transplant. 2007 Sep;40(6):541-7. (PMID: 17637692)
      Blood. 2008 Feb 15;111(4):1827-33. (PMID: 18048644)
      Korean J Intern Med. 1998 Feb;13(1):60-3. (PMID: 9538634)
      Bone Marrow Transplant. 2003 Sep;32(6):543-8. (PMID: 12953124)
      Am J Pathol. 1987 Jan;126(1):114-25. (PMID: 3101503)
      J Clin Oncol. 1992 Feb;10(2):237-42. (PMID: 1732424)
    • Contributed Indexing:
      Keywords: Busulfan; Drug therapy; Fludarabine; Precursor cell lymphoblastic leukemia-lymphoma
    • Accession Number:
      0 (Myeloablative Agonists)
      FA2DM6879K (Vidarabine)
      G1LN9045DK (Busulfan)
      P2K93U8740 (fludarabine)
    • Publication Date:
      Date Created: 20120310 Date Completed: 20120709 Latest Revision: 20211021
    • Publication Date:
      20240628
    • Accession Number:
      PMC3295992
    • Accession Number:
      10.3904/kjim.2012.27.1.72
    • Accession Number:
      22403503